Navigation Links
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy. These ITT data were presented today in two late breaker oral presentations at the 27th Annual Scientific Meeting of The Obesity Society in Washington, D.C.

Results showed that, on an ITT basis,

  • Approximately 25-33% lost 10% or more of their body weight and 12-16% lost at least 15%; and
  • Obese patients on Contrave demonstrated significant improvements in important markers of cardiometabolic risk including waist circumference, HDL and triglycerides

"The data presented today and on Saturday provide a deeper view of Contrave, and what we believe is a balanced efficacy and safety profile," said Eduardo Dunayevich, M.D., Chief Medical Officer of Orexigen. "These findings should help clinicians assess the potential value of Contrave pharmacotherapy in managing obesity and support our belief that if approved, Contrave could meet the broad range of needs of this patient population by virtue of its efficacy, safety and benefits on key markers of cardiometabolic risk."

Additional data from today's late breaker presentations are outlined in the below table:

    Efficacy Result(+)
                                    COR-I                       COR-II
    --------------------------------------------------------------------------
                               PBO 
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Pa. , July 23, 2014 /PRNewswire/ ... today announced successful results from its randomized, ... in women with biopsy-proven cervical intraepithelial neoplasia ... types 16 or 18. Treatment with VGX-3100, ... of CIN2/3 to CIN1 or no disease, ...
(Date:7/23/2014)... WASHINGTON , July 23, 2014  Nearly 8,000 ... for Cardinal Health,s annual Retail Business Conference (RBC), ... & Convention Center. This year,s event encourages pharmacists to ... in their communities and for their future. ... pharmacy owners to network with their peers and learn ...
(Date:7/23/2014)... July 23, 2014  Mevesi Inc. would like ... This integration provides pharmacies with the ability to ... prospective patients. Mevesi,s solutions provide ... data to define target marketing campaigns. This coupled ... available within the Digital Marketing, Population Management, and ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Mevesi Enhances Solutions with Variable Print Media Capabilities! 2
(Date:7/23/2014)... Steven Reinberg ... News) -- Many obese and overweight American children and ... weight is fine, U.S. health officials reported Wednesday. ... outcomes, such as high blood pressure, high cholesterol and ... at the U.S. Centers for Disease Control and Prevention,s ...
(Date:7/23/2014)... Home Care Assistance Calgary , North ... proud to announce the next installment in its renowned ... range of health and wellness-related fields. The upcoming webinar ... Nancy Kriseman, and will cover the most common causes ... becoming more self-aware. In particular, Nancy will discuss mindfulness ...
(Date:7/23/2014)... supports a growing body of research suggesting a ... in treating postmenopausal breast cancer, with fewer detrimental ... standard anti-hormone therapies. The study will be published ... Reproductive Biology and Endocrinology . , Breast ... women in the United States. Approximately 70% of ...
(Date:7/23/2014)... The American Telemedicine Association (ATA) ... annual meeting and tradeshow focused exclusively on telemedicine, ... over 5,000 attendees and more than 250 cutting-edge ... 2015, in Los Angeles. , ATA’s annual meeting ... from researchers, clinicians, hospital and university administrators, program ...
(Date:7/23/2014)... X syndrome ( FXS ) is a genetic disorder ... on the autistic spectrum, as well as cognitive deficits. ... impairment and the most common cause of autism. , ... have published a study that sheds light ... online today (July 23) in the Journal of ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... released by the U.S. Centers for Disease Control and Prevention ... birth defects in the country.// ,"It helps to ... the import they have on families around the country," said ... March of Dimes Birth Defects Foundation in White Plains, New ...
... Southampton General Hospital says that by taking adequate amounts of ... their children.// In a study of 198 mothers, it was ... their kids had greater bone densities. ,"This is ... mother's vitamin D levels before," said lead researcher Professor Cyrus ...
... in the crown of physical exercisers. A new study in ... wound-healing process by as much as 25 percent//. ... will become infected. ,The results appear in a ... ,This is the first time such an enhancement associated ...
... The Journal of Science has published a research report ... mood and sleep, and also plays an important// role ... suffering from depressive illnesses, the best pharmacological treatments are ... p11, is closely related to serotonin transmission in the ...
... Zealand Veterinary Association is on war path against Australian euthanasia ... get deadly drugs//. ,Dr Nitschke told more than ... option for those wanting to die was to approach a ... Veterinary Association chief executive Murray Gibb said such advice was ...
... majority of Californian adults are of the opinion, that ... the State’s Public Schools//, according to a survey, by ... 75% of respondents opted for programs with information on ... 17% favored information on mere abstinence programs. At least ...
Cached Medicine News:Health News:Wounds Heal 25% Faster In Older Adults Who Exercise Regularly 2Health News:Wounds Heal 25% Faster In Older Adults Who Exercise Regularly 3Health News:Scientists Identify Gene Responsible For Depression 2Health News:Kiwi veterinarians angry Over Doctor's Advice 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... original Magstim design the new Magstim 200 ... of knowledge and expertise gathered in both ... an innovative design that will help further ... system of preferred choice. Ergonomic modular ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: